Effect of polymorphisms of IL-17A, -17F and MIF genes on CpG island hyper-methylation (CIHM) in the human gastric mucosa

International Journal of Molecular Medicine

Volumn 24, Issue 4, 2009, Pages 563-569

  Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Nakamura, Masakatsu ^a   Yamashita, Hiromi ^a   Yoshioka, Daisuke ^a   Okubo, Masaaki ^a   Yonemura, Joh ^a   Maeda, Yoshiteru ^a   Maruyama, Naoko ^a   Kamano, Toshiaki ^a   Kamiya, Yoshio ^a   Fujita, Hiroshi ^a   Nakagawa, Yoshihito ^a   Nagasaka, Mitsuo ^a   Iwata, Masami ^a   Hirata, Ichiro ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

CpG island hyper methylation; Genetic polymorphism; Interleukin 17; Macrophage migration inhibitory factor; Stomach

Indexed keywords

ALANINE; CYSTEINE; DEATH ASSOCIATED PROTEIN KINASE; GLYCINE; INTERLEUKIN 17; INTERLEUKIN 17F; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN P14; PROTEIN P16; THREONINE; UVOMORULIN;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; STOMACH CARCINOGENESIS; STOMACH MUCOSA;

AGED; CPG ISLANDS; DNA METHYLATION; FEMALE; GASTRIC MUCOSA; GENOTYPE; HUMANS; INTERLEUKIN-17; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 70350783612     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000266     Document Type: Article

References (53)

1. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 4: 536-540, 1994.
2. Ahuja N, Li Q, Mohan AL, Baylin SB and Issa JP: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 23: 5489-5494, 1998.
3. Rizos H, Darmanian AP, Mann GJ and Kefford RF: Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19: 2978-2985, 2000.
4. Tannapfel A, Busse C, Weinans L, et al: INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 20: 7104-7109, 2001.
5. Toyota M, Ahuja N, Suzuki H, et al: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59: 5438-5442 1999.
6. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY and Rhyu MG: CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61: 2847-2851, 2001.
7. Chan AO, Lam SK, Wong BC, et al: Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 52: 502-506, 2003.
8. Raveh T and Kimchi A: DAP kinase - a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 264: 185-192, 2001.
9. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A and Schneider-Stock R: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol 26: 1493-1500, 2005.
10. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S and Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 94: 360-364, 2003.
11. Maekita T, Nakazawa K, Mihara M, et al: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995, 2006.
12. Tahara T, Arisawa T, Shibata T, et al: Increased number of methylated CpG islands correlates with Helicobacter pylori infection, histological and serological severity of chronic gastritis. Eur J Gastroenterol Hepatol (In press).
13. Tahara T, Arisawa T, Shibata T, et al: Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 75: 54-61, 2007.
14. Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y and Tajiri H: CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 13: 35-41, 2008.
15. Nakajima T, Maekita T, Oda I, et al: Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 15: 2317-2321, 2006.
16. Issa JP: GpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249: 101-118, 2000.
17. Meyer-ter-Vehn T, Covacci A, Kist M and Pahl HL: Helicobacter pylori activates mitogen-activated protein kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J Biol Chem 275: 16064-16072, 2000.
18. Seo JH, Lim JW, Kim H and Kim KH: Helicobacter pylori in a Korean isolate activates mitogen-activated kinase, AP-1 and NF-κB and induces chemokine expression in gastric epithelial AGS cells. Lab Invest 84: 49-62, 2004.
19. Kawaguchi M, Adachi M, Oda N, Kokubu F and Huang SK: IL-17 cytokine family. J Allergy Clin Immunol 114: 1265-1274, 2004.
20. Kawaguchi M, Takahashi D, Hizawa N, et al: IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 117: 795-801, 2006.
21. Bloom BR and Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82, 1966.
22. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6: 164-170, 2000.
23. Donn R, Alourfi Z, De Benedetti F, et al: Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46: 2402-2409, 2002.
24. Amoli MM, Donn RP, Thomson W, et al: Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 29: 1671-1673, 2002.
25. Luzza F, Parrello T, Monteleone G, et al: Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 165: 5332-5337, 2000.
26. Xia HHX, Lam SK, Huang XR, et al: Helicobacter pylori infection is associated with increased expression of macrophage migration inhibitory factor by epithelial cells, T cells and macrophages in gastric mucosa. J Infect Dis 190: 293-302, 2004.
27. Arisawa T, Tahara T, Shibata T, et al: Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and chronic gastritis. Int J Mol Med 20: 539-544, 2007.
28. Arisawa T, Tahara T, Shibata T, et al: Association between genetic polymorphisms in interleukin-17A and -17F gene and gastro-duodenal ulcer diseases. Scand J Gastroenterol (In press).
29. Arisawa T, Tahara T, Shibata T, et al: Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncol Rep 19: 223-228, 2008.
30. Shibata T, Tahara T, Arisawa T and Hirata I: Genetic polymorphisms of interleukin-17A and -17F gene in gastric carcinogenesis. Hum Immunol (In press).
31. Tahara T, Shibata T, Nakamura M, et al: MTHFR 677 T carrier influences the methylation status of H. pylori infected gastric mucosa in older subjects. Dig Dis Sci (In press).
32. Esteller M, Tortola S, Toyota M, et al: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133, 2000.
33. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
34. Katzenellenbogen RA, Baylin SB and Herman JG: Hyper-methylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-4353, 1999.
35. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH and Kim JS: Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 163: 1551-1556, 2003.
36. Bloom BR and Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153: 80-82, 1966.
37. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56: 72-77, 1966.
38. Leech M, Metz C, Hall P, et al: Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42: 1601-1608, 1999.
39. Bernhagen J, Calandra T and Bucala R: The emerging role of MIF in septic shock and infection. Biotherapy 8: 123-127, 1995.
40. Donnelly SC, Bucala R, Metz CN, et al: Macrophage migration inhibitory factor and acute lung injury. Chest 116: S111, 1999.
41. Tulic MK, Wale JL, Holt PG and Sly PD: Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 22: 604-612, 2000.
42. Gereda JE, Leung DY, Thatayatikom A, et al: Relation between house-dust endotoxin exposure, type-1 T-cell development, and allergen sensitization in infants at high risk of asthma. Lancet 355: 1680-1683, 2000.
43. Plant BJ, Gallagher CG, Bucala R, et al: Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. Am J Respir Crit Care Med 172: 1412-1415, 2005.
44. Donn RP, Plant D, Jury F, et al: Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123: 484-487, 2004.
45. Hizawa N, Yamaguchi E, Takahashi D, Nishihara J and Nishimura M: Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy. Am J Respir Crit Care Med 169: 1014-1018, 2004.
46. Huang XR, Chun HCW, Chen YX, et al: Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 121: 619-630, 2001.
47. He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55: 797-802, 2006.
48. Bamford KB, Fan X, Crowe SE, et al: Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 88: 70-74, 1998.
49. Calandra T, Bernhagen J, Mitchell RA and Bucala R: Macrophage is an important and previously unrecognized source of macrophage-migration inhibitory factor. J Exp Med 179: 1895-1902, 1994.
50. Bacher M, Mets CN, Calandra T, et al: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93: 7849-7854, 1996.
51. Benigni F, Atsumi T, Calandra T, et al: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 106: 1291-1300, 2000.
52. Abe R, Peng T, Sailors J, Bucala R and Metz CN: Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 166: 747-753, 2001.
53. Baugh JA, Chitnis S, Donnelly SC, et al: A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3: 170-176, 2002.